academia_top4

Steroid-toxicity
can now be measured
in practice

Practitioners can monitor steroid-toxicity in the background

Practicing physicians have grappled with steroids for decades. In recent years, an explosion of innovative strategies aimed at tapering or even eliminating steroids for immune-mediated inflammatory diseases has offered an array of alternative treatments. Therapeutic pipelines are full of exciting biologics, targeted agents and treatment strategies ready for clinical development.

Essential to adoption of new and approved treatments to help the largest numbers of patients is the ability to equip clinicians to monitor for emerging steroid-toxicity.  The core of the Steritas mission is to offer the same scientifically rigorous clinical outcome assessments (COAs) deployed in research, for use in routine clinical settings. Using data routinely collected in the clinic, the GTI-MD can be integrated into electronic medical record (EMR) systems, and equip doctors to detect emerging steroid-toxicity before it is clinically evident in their patients.  The GTI-MD works in the background and alerts the physician only when steroid- toxicity rises to a dangerous level. Validated steroid-toxicity scores can support prior authorization of steroid alternatives that are critical to patient well-being. 

The STOX Suite: a range of COAs to suit varying needs


Whether the end-goal is to improve clinical outcomes assessment in routine practice or to strengthen the evidence gathered in prospective studies and clinical trials, the STOXTM Suite, our collection of clinical outcome assessment (COA), can help you improve the accuracy, reproducibility and efficiency of steroid-toxicity assessment.

  • The GTI: calculates change scores across nine health domains in adults
  • The GTI-MD: quantifies change across four metabolic domains
  • The pGTI: captures the change scores in nine health domains in children 

The STOX Suite is the first collection of validated clinical outcome assessments (COAs) of steroid-toxicity. Each COA can be licensed alone or as a bundle for both retrospective and prospective applications. These applications include:

  • Clinical trials
  • Academic studies
  • Health economics and outcomes research (HEOR)
  • Real-world experiences
  • Clinical practice

 

The STOX Suite (GTI, pGTI and GTI-MD) has been licensed in 25+ disease indications, across 1100 sites in 80 countries across the world.

Steritas_GTI_PrimaryCare_Warning_1920x1080pxl_V3
"If you ask the doctor and patient what they want most of all, their unanimous answer will be, дnot to have to use steroids."

Murray Urowitz, MD FRCP(C)

Professor of Medicine at the University of Toronto

Senior Staff Rheumatologist at the Toronto Western Hospital

Senior Scientist at Krembil Research Institute

Clinical Director, Centre for Prognosis Studies in the Rheumatic Diseases, University Health Network

Learn More
"Steroid toxicity is rampant and it can be fatal -  bringing it onto the radar screen of the practicing physician is really, really important."

James T. Rosenbaum, MD

Chief of Ophthalmology emeritus at the Legacy Devers Eye Institute, Portland, Oregon

Learn More
"A version of the GTI that could be built into the EPR and generate a big red pop-up that takes up the whole screen and urges providers to record data and to think differently about the prescription would provide the wake-up call that is so often needed."

Michelle Petri, MD MPH

Professor of Medicine at the Johns Hopkins University School of Medicine

Learn More
"Steroid-toxicity is a huge problem amongst our patients. When they have to be on these drugs for one or more years to keep the disease suppressed they experience many, many complicated side effects, some of which are life threatening."

Dedee Murrell, MD DSc

Head of the Department of Dermatology and St George Hospital, University of New South Wales, Sydney, Australia

Professorial Fellow at The George Institute for Global Health

Learn More
"Glucocorticoids cause many major side effects such as mental disturbance and gastric ulcers, but we also have to be conscious of the adverse effects - just one milligram of prednisone is harmful to the metabolism."

Yoshiya Tanaka, MD PhD

Professor and Chairman of the First Department of Internal Medicine, School of Medicine. Dean of Graduate School of Medical Science, University of Occupational and Environmental Health, Japan

Learn More

Make the STOX Suite part of your care quality program

Sign up for our webinar series to learn more

Register today